Targeted Approaches to T-Cell Lymphoma

Abstract

The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.

Keywords: immunotherapy; monoclonal antibodies; novel agents.

Figure 1

Targets of novel T-cell lymphoma therapy. PI3K, Phosphoinositide 3-kinase; NPM, Nucleophosmin; ALK, Anaplastic lymphoma kinase; JAK, Janus kinases; STAT, signal transducer and activator of transcription proteins; HDAC, Histone deacetylase; DMT, DNA methyltransferase.